Diagnostic accuracy of fused positron emission tomography/magnetic resonance mammography: Initial results

British Journal of Radiology

Volumn 84, Issue 998, 2011, Pages 126-135

  Heusner, Till Alexander ^a   Hahn, S ^a   Jonkmanns, C ^a   Kuemmel, S ^a   Otterbach, F ^a   Hamami, M E ^a   Stahl, A R ^a   Bockisch, A ^a   Forsting, M ^a   Antoch, G ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST LESION; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER PROGRAM; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MCNEMAR TEST; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SURGICAL APPROACH;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; RADIOPHARMACEUTICALS; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 78751687695     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/93330765     Document Type: Article

References (42)

1. Van Goethem M, Schelfout K, Kersschot E, Colpaert C, Verslegers I, Biltjes I, et al. MR mammography is useful in the preoperative locoregional staging of breast carcinomas with extensive intraductal component. Eur J Radiol 2007;62:273-82. (Pubitemid 46560342)
2. Rim A, Chellman-Jeffers M. Trends in breast cancer screening and diagnosis. Cleve Clin J Med 2008;75:S2-9.
3. Kuhl CK, Braun M. [Magnetic resonance imaging in preoperative staging for breast cancer: pros and cons]. Radiologe 2008;48:358-66.
4. Warner E, Plewes DB, Shumak RS, Catzavelos GC, Di Prospero LS, Yaffe MJ, et al. Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 2001;19:3524-31.
5. Wright H, Listinsky J, Rim A, Chellman-Jeffers M, Patrick R, Rybicki L, et al. Magnetic resonance imaging as a diagnostic tool for breast cancer in premenopausal women. Am J Surg 2005;190:572-5. (Pubitemid 41306078)
6. Rausch DR, Hendrick RE. How to optimize clinical breast MR imaging practices and techniques on your 1.5-T system. Radiographics 2006;26:1469-84.
7. Van Goethem M, Tjalma W, Schelfout K, Verslegers I, Biltjes I, Parizel P. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol 2006;32:901-10. (Pubitemid 44636925)
8. Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999;213:881-8.
9. Kuhl C, Kuhn W, Braun M, Schild H. Pre-operative staging of breast cancer with breast MRI: one step forward, two steps back? Breast 2007;16:S34-44.
10. Simonelli LE, Fowler J, Maxwell GL, Andersen BL. Physical sequelae and depressive symptoms in gynecologic cancer survivors: meaning in life as a mediator. Ann Behav Med 2008;35:275-84.
11. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22:4357-68.
12. Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003;229:526-33.
13. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004;45:357-65.
14. Moy L, Noz ME, Maguire GQ Jr, Ponzo F, Deans AE, Murphy-Walcott AD, et al. Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans. Clin Nucl Med 2007;32:194-8.
15. Moy L, Ponzo F, Noz ME, Maguire GQ Jr, Murphy-Walcott AD, Deans AE, et al. Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med 2007;48:528-37. (Pubitemid 47571406)
16. Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30:588-96. (Pubitemid 36559838)
17. Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med 2005;46:1819-24.
18. Tardivon AA, Athanasiou A, Thibault F, El Khoury C. Breast imaging and reporting data system (BIRADS): magnetic resonance imaging. Eur J Radiol 2007;61:212-15.
19. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997;3:780-2.
20. Furman-Haran E, Grobgeld D, Margalit R, Degani H. Response of MCF7 human breast cancer to tamoxifen: evaluation by the three-time-point, contrast-enhanced magnetic resonance imaging method. Clin Cancer Res 1998;4:2299-304. (Pubitemid 28477892)
21. Hauth EA, Jaeger H, Maderwald S, Stockamp C, Muhler A, Kimmig R, et al. Evaluation of quantitative parametric analysis for characterization of breast lesions in contrast-enhanced MR mammography. Eur Radiol 2006;16:2834-41.
22. Hauth EA, Stockamp C, Maderwald S, Muhler A, Kimmig R, Jaeger H, et al. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. Clin Imaging 2006;30:160-5.
23. Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, et al. Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 2008;49:1215-22.
24. Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: A guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer 2008;44:2742-52.
25. Stoutjesdijk MJ, Boetes C, Jager GJ, Beex L, Bult P, Hendriks JH, et al. Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst 2001;93:1095-102.
26. Swayampakula AK, Dillis C, Abraham J. Role of MRI in screening, diagnosis and management of breast cancer. Expert Rev Anticancer Ther 2008;8:811-17.
27. Winnekendonk G, Krug B, Warm M, Gohring UJ, Mallmann P, Lackner K. Diagnostic value of preoperative contrast-enhanced MR imaging of the breast. Rofo 2004;176:688-93. (In German.)
28. Taieb S, Ceugnart L. [Breast MR imaging: validated indications and unsolved problems]. Bull Cancer 2008;95:147-52.
29. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000;18:3495-502.
30. Van Goethem M, Schelfout K, Kersschot E, Colpaert C, Weyler J, Verslegers I, et al. Comparison of MRI features of different grades of DCIS and invasive carcinoma of the breast. JBR-BTR 2005;88:225-32.
31. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471-80.
32. Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G, et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 2002;67:765-75. (Pubitemid 34765665)
33. Jonson SD, Welch MJ. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 1998;42:8-17.
34. Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. 18F-Fluoroestradiol. Semin Nucl Med 2007;37:470-6.
35. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998;25:1429-34.
36. Hammer C, Fanning A, Crowe J. Overview of breast cancer staging and surgical treatment options. Cleve Clin J Med 2008;75:S10-16.
37. Wang Y, Chiu E, Rosenberg J, Gambhir SS. Standardized uptake value atlas: characterization of physiological 2-deoxy-2-[18F]fluoro-D-glucose uptake in normal tissues. Mol Imaging Biol 2007;9:83-90. (Pubitemid 46336223)
38. Pichler BJ, Judenhofer MS, Catana C, Walton JH, Kneilling M, Nutt RE, et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 2006;47:639-47. (Pubitemid 46768465)
39. Pichler BJ, Judenhofer MS, Pfannenberg C. Multimodal imaging approaches: PET/CT and PET/MRI. Handb Exp Pharmacol 2008;109:32.
40. Pichler BJ, Judenhofer MS, Wehrl HF. PET/MRI hybrid imaging: devices and initial results. Eur Radiol 2008;18:1077-86.
41. Pichler BJ, Wehrl HF, Kolb A, Judenhofer MS. Positron emission tomography/magnetic resonance imaging: the next generation of multimodality imaging? Semin Nucl Med 2008;38:199-208.
42. Beyer T, Weigert M, Quick HH, Pietrzyk U, Vogt F, Palm C, et al. MR-based attenuation correction for torso-PET/MR imaging: pitfalls in mapping MR to CT data. Eur J Nucl Med Mol Imaging 2008;35:1142-6.